ClinicalTrials.gg
RecruitingNCT06930625OXTEND™-03Updated Nov 17, 2026

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

A Phase 3 interventional study of Debio 4126 and Placebo in Acromegaly, sponsored by Debiopharm International SA. Recruiting at 74 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Debiopharm International SA (part of Debiopharm) · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.
Updated Nov 17, 2026Site recruiting status changed1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
119
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 64 studies in Acromegaly with a site in United States — 5 open to participants now, 5 under way, 1 of them phase 3. Acromegaly · United States.

Planned enrollment
9th of 43
119 · median 59
Started
2025
with 2 others
Phase 3
15 of 64
1 open now
Registered
61st of 64
by date

Among the 64 studies in Acromegaly with a site in United States, this one is the 9th largest by planned enrollment of the 43 interventional ones that give a count, is one of 3 that started in 2025, is one of 15 in phase 3, and was the 61st registered.

Acromegaly

202 studies on the registry are indexed under Acromegaly; 19 are open to participants now.

Browse Acromegaly studies →

Open to participants now

5 of the 64 studies in Acromegaly with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Acromegaly studies recruiting now, 7 (50%) set no upper age limit and 5 (36%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Acromegaly with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this study is to assess the effect of Debio 4126 in the maintenance of the levels of insulin-like growth factor 1 (IGF-1) ≤1x upper limit of normal (ULN) in the double-blind period (Period 1) in comparison to placebo at week 36.

03

Conditions studied

  • Acromegaly

Keywords

  • IGF-1
  • Growth hormone
  • Pituitary gland
  • Gigantism
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients ≥18 years of age
  2. Patients who are receiving octreotide or lanreotide monotherapy for acromegaly for at least 6 months, at a stable dose for the last 12 weeks.
  3. IGF-1 at screening ≤1x
  4. Acromegaly diagnosis, defined as per protocol
  5. Adequate bone marrow, hepatic and renal function
  6. To enter Period 2 (Arms A and B): IGF-1 ≤1x ULN at Week 34, or up to Week 48 when treated with rescue medication
  7. Other protocol-defined criteria apply

Exclusion criteria

Exclusion criteria

  1. Compression of optic chiasm causing visual defects
  2. Symptomatic cholelithiasis or bile duct dilatation
  3. Planned cholecystectomy during the trial duration
  4. Acute or chronic pancreatitis
  5. Pituitary radiotherapy
  6. Uncontrolled hypothyroidism
  7. Uncontrolled diabetes
  8. Pituitary surgery within 6 months before screening or planned on trial
  9. Treatment with pasireotide within 6 months prior to screening, pegvisomant or dopamine agonists within 3 months prior to screening
  10. Recent or ongoing cardiovascular or thromboembolic diseases including heart failure, myocardial infarction, stroke, certain arrythmias, pulmonary embolism
  11. Other protocol-defined criteria apply
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
119 participants (estimated)

Study arms

  • Experimental
    Arm A: Debio 4126

    During Period 1 (double-blind treatment period), participants will receive an intramuscular (IM) injection of Debio 4126 once every 12 weeks over a total of 36 weeks (3 injections in total). Participants whose acromegaly is not well controlled may receive rescue medication. Eligible participants (IGF-1 ≤1x ULN on Week 34) will enter Period 2 on Week 36 and receive an open-label Debio 4126 injection once every 12 weeks over a total of 24 to 60 weeks (between 2 and 5 injections in total). Participants with IGF-1 \>1x ULN may receive rescue medication until Week 48, and may become eligible for Period 2 if their IGF-1 is ≤1x ULN.

    Drug: Debio 4126

  • Placebo comparator
    Arm B: Placebo + Debio 4126

    During Period 1 (double-blind treatment period), participants will receive an IM injection of placebo once every 12 weeks over a total of 36 weeks (3 injections in total). Participants whose acromegaly is not well controlled may receive rescue medication. Eligible participants (IGF-1 ≤1x ULN on Week 34) will enter Period 2 on Week 36 and receive an open-label Debio 4126 injection once every 12 weeks over a total of 24 to 60 weeks (between 2 and 5 injections in total). Participants with IGF-1 \>1x ULN may receive rescue medication until Week 48, and may become eligible for Period 2 if their IGF-1 is ≤1x ULN.

    Drug: Debio 4126 · Drug: Placebo

  • Experimental
    Arm C: Debio 4126 (Open-Label Treatment Period)

    During the Treatment Period, participants will receive an IM injection of Debio 4126 once every 12 weeks over a total of between 60 and 96 weeks (between 5 and 8 injections in total).

    Drug: Debio 4126

Interventions

  • DrugDebio 4126

    IM injection, a 12-week extended-release formulation of octreotide

  • DrugPlacebo

    IM injection of mannitol suspension

06

What researchers measure

Primary outcomes

  1. Double-blind Period: Percentage of Participants With IGF-1 ≤1x ULN

    Time frame: 36 Weeks

Secondary outcomes

  1. Arm C: Percentage of Participants With IGF-1 ≤1x ULN

    Time frame: 36 Weeks

  2. Percent Change From Baseline in IGF-1 Values

    Time frame: Up to 108 Weeks

  3. Percentage of Participants With IGF-1 ≤1x ULN

    Time frame: Up to 108 Weeks

  4. Percentage of Participants With Growth Hormone (GH) Level <1 ng/mL

    Time frame: Up to 108 Weeks

  5. Double-blind Period: Percentage of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE)

    Time frame: Up to 36 Weeks

  6. Percentage of Participants Who Experienced at Least One TEAE

    Time frame: Up to 113 Weeks

  7. Local Tolerability of Debio 4126 as Assessed by Erythema, Swelling, and Induration at the Injection Site Using Investigator Assessment

    Time frame: Up to 108 Weeks

  8. Local Tolerability of Debio 4126 as Assessed by Pain at Injection Site Based on Pain Visual Analog Scale (VAS) Score

    Time frame: Up to 108 Weeks

  9. Double-blind Period: Percentage of Participants Taking Rescue Medication

    Time frame: Up to 36 Weeks

  10. Trough Plasma Concentration (Ctrough) of Debio 4126

    Time frame: Up to 96 Weeks

07

Study locations

73 of 74 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Jun 2028, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2025
First posted
Apr 16, 2025
StartActual
Nov 26, 2025
Primary completionEst.
Jun 2028
CompletionEst.
Mar 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. 2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • NYU Grossman School of Medicine · New York, United StatesNot yet recruiting→Recruiting
  • Hospital Medical Center L2 · Brasília, BrazilNot yet recruiting→Recruiting
Show site
  • Hospital Medical Center L2 · Brasília, Brazil
across 2 updates, Oct 23, 2026 – Nov 17, 2026
Show all 2 updates
  1. Nov 17, 2026
    Hospital Medical Center L2 is now Recruiting
    + 1 other change: verification date
  2. Oct 23, 2026
    1 site added. NYU Grossman School of Medicine is now Recruiting
    Show site
    • Hospital Medical Center L2 · Brasília, Brazil
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06930625
Responsible party
Sponsor
First posted
Apr 16, 2025
Start date
Nov 26, 2025
Primary completion
Jun 2028 (estimated)
Completion
Mar 2029 (estimated)
Last update
Nov 17, 2026

Study contacts

Debiopharm International S.A
Contact
clinicaltrials@debiopharm.com
+41 21 321 01 11

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion